KP 483
Alternative Names: KP-483Latest Information Update: 05 Dec 2023
At a glance
- Originator Kaken Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Sep 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Recurrent) in Japan (PO) (jRCT2031220311)